Overview

Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma

Status:
Unknown status

Trial end date:
2021-10-31

Target enrollment:

Participant gender:

Summary

Open-label, single-arm, multi-center, Phase IIa study to evaluate the efficacy, safety, and immunological response of OBP 301 in patients with unresectable/unresected metastatic melanoma. This proof of concept study will be undertaken in male and female patients with unresectable Stage III and IV melanoma. Patients with unresectable/unresected mucosal melanoma may be enrolled after consultation with the Medical Monitor.

Phase:

Phase 2

Details

Lead Sponsor:

Syneos Health

Collaborator:

Oncolys BioPharma Inc